Literature DB >> 7332119

Malignant hyperthermia-triggering liability of selected inhalant anesthetics in swine.

C J McGrath, W E Rempel, C R Jessen, P B Addis, A J Crimi.   

Abstract

Twenty pigs, known to be malignant hyperthermia (MH)-susceptible by previous MH-positive [MH(+)] reactions to halothane testing, were given 5 inhalant anesthetics. The number of MH(+) responses evoked by the different anesthetics varied. In response to halothane, isoflurane, and enflurane, MH(+) reactions were exhibited by 12, 11, and 7 pigs, respectively. The number of MH(+) reactions to nitrous oxide (0) and methoxyflurane (1) was significantly (P = 0.02) less. In the present study, all 4 halogenated-hydrocarbon volatile liquid inhalant anesthetics were capable of evoking a MH(+) reaction in susceptible pigs.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332119

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  5 in total

1.  Bibliography for the control of anxiety, fear and pain in dentistry.

Authors:  G L McAlister; C L Richardson
Journal:  Anesth Prog       Date:  1982 Nov-Dec

Review 2.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 3.  Desflurane. A review of its pharmacodynamic and pharmacokinetic properties and its efficacy in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

4.  Canine malignant hyperthermia: diagnosis of susceptibility in a breeding colony.

Authors:  P J O'brien; P H Cribb; R J White; E D Olfert; J E Steiss
Journal:  Can Vet J       Date:  1983-06       Impact factor: 1.008

Review 5.  Management of malignant hyperthermia: diagnosis and treatment.

Authors:  Daniel Schneiderbanger; Stephan Johannsen; Norbert Roewer; Frank Schuster
Journal:  Ther Clin Risk Manag       Date:  2014-05-14       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.